Literature DB >> 8348754

Inhibitor(s) of natural anti-cardiolipin autoantibodies.

Z Kra-Oz1, M Lorber, Y Shoenfeld, Y Scharff.   

Abstract

IgG fractions were purified on Sepharose anti-human IgG column from eight sera of healthy donors, having no anti-cardiolipin (aCL) activity as measured by anti-cardiolipin ELISA assay (aCL-ELISA). All the IgG fractions, after elution with 4.9 M MgCl2, reacted with CL. The antigen-binding characteristics of the IgG fractions purified from normal human serum (NHS) were similar to those of IgG fractions purified from sera of four patients with the anti-phospholipid syndrome (APLS). Competition assay confirmed the specificity of the binding of the purified IgG fractions to CL. The same results have been achieved with IgG fractions purified on Sepharose Protein-A column. The binding to CL was completely inhibited by either whole NHS and sera from various animal species, or by beta 2-glycoprotein I (beta 2-GPI). Our results support the notion of the existence of both natural anti-CL antibodies and serum inhibitor(s) in sera of healthy individuals. It is conceivable that in part the pathogenesis of APLS entails defects in the natural inhibitors of aCL antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348754      PMCID: PMC1554831          DOI: 10.1111/j.1365-2249.1993.tb07977.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

2.  Anticardiolipin antibodies and binding of anionic phospholipids and serum protein.

Authors:  E N Harris; S Pierangeli; J Barquinero; J Ordi-Ros
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

Review 3.  Are bacterial endotoxins involved in autoimmunity by CD5+ (Ly-1+) B cells?

Authors:  N van Rooijen
Journal:  Immunol Today       Date:  1989-10

4.  A common anti-cardiolipin antibody idiotype in autoimmune disease: identification using a mouse monoclonal antibody directed against a naturally-occurring anti-phospholipid antibody.

Authors:  M Sutjita; A Hohmann; R Comacchio; M L Boey; J Bradley
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

Review 5.  Studies on natural antibodies and autoantibodies.

Authors:  S Avrameas; G Dighiero; P Lymberi; B Guilbert
Journal:  Ann Immunol (Paris)       Date:  1983 Jul-Aug

6.  Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.

Authors:  M Blank; J Cohen; V Toder; Y Shoenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 7.  Antiphospholipid antibody syndrome: immunologic and clinical aspects.

Authors:  L R Sammaritano; A E Gharavi; M D Lockshin
Journal:  Semin Arthritis Rheum       Date:  1990-10       Impact factor: 5.532

8.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 9.  Antiphospholipid antibodies--autoantibodies with a difference.

Authors:  E N Harris; R A Asherson; G R Hughes
Journal:  Annu Rev Med       Date:  1988       Impact factor: 13.739

10.  Distribution of two common idiotypes of anticardiolipin antibodies in sera of patients with primary antiphospholipid syndrome, systemic lupus erythematosus and monoclonal gammopathies.

Authors:  I Krause; J Cohen; M Blank; R Bakimer; A Cartman; A Hohmann; G Valesini; R A Asherson; M A Khamashta; G R Hughes
Journal:  Lupus       Date:  1992-02       Impact factor: 2.911

View more
  9 in total

Review 1.  Cardiolipin, coagulation, co-factors and connective tissue disease.

Authors:  R S Pereira
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

2.  Anti-endothelial cell antibodies in systemic vasculitis and systemic lupus erythematosus (SLE): effects of heat inactivation on binding and specificity.

Authors:  D P D'Cruz; G Keser; H Direskeneli; M A Khamashta; G R Hughes
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

3.  Role of molecular mimicry and polyclonal cell activation in the induction of pathogenic β2-glycoprotein I-directed immune response in Balb/c mice upon hyperimmunization with tetanus toxoid.

Authors:  Marijana Stojanović; Vladimir Petrušić; Irena Zivković; Aleksandra Inić-Kanada; Ivana Stojićević; Emilija Marinković; Ljiljana Dimitrijević
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

5.  Heat treatment of normal human sera reveals antibodies to bactericidal permeability-inducing protein (BPI).

Authors:  A A Brownlee; C M Lockwood
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

6.  Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies.

Authors:  A Kenderov; V Minkova; D Mihailova; N Giltiay; S Kyurkchiev; I Kehayov; M Kazatchkine; S Kaveri; A Pashov
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

7.  Natural hidden autoantibodies to tissue transglutaminase cross-react with fibrinogen.

Authors:  Ingrid M Zöller-Utz; Birgit Esslinger; Anja Schulze-Krebs; Walburga Dieterich
Journal:  J Clin Immunol       Date:  2009-11-27       Impact factor: 8.317

Review 8.  Hidden autoantibodies.

Authors:  M Lorber; Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2000-02       Impact factor: 10.817

Review 9.  Antiphospholipid antibodies: paradigm in transition.

Authors:  Lawrence L Horstman; Wenche Jy; Carlos J Bidot; Yeon S Ahn; Roger E Kelley; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; Seyed Ali Mousavi; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2009-01-20       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.